AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Diabetic Neuropathy Drugs Market 2019-2023 - Evolving Opportunities with DAIICHI SANKYO COMPANY LIMITED and Eli Lilly and Company | Technavio

November 14, 2019 GMT
Global Diabetic Neuropathy Drugs Market 2019-2023 - Evolving Opportunities with DAIICHI SANKYO COMPANY LIMITED and Eli Lilly and Company | Technavio
Global Diabetic Neuropathy Drugs Market 2019-2023 - Evolving Opportunities with DAIICHI SANKYO COMPANY LIMITED and Eli Lilly and Company | Technavio

LONDON--(BUSINESS WIRE)--Nov 14, 2019--

The global diabetic neuropathy drugs market size will grow by USD 866.72 million during 2019-2023. This market report provides a detailed analysis of the market by mechanism of action (calcium channel alpha-2-delta ligand, SNRIs and TCAs, and others) and geography (Asia, Europe, North America, and ROW).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191114005318/en/

Technavio has announced its latest market research report titled global diabetic neuropathy drugs market 2019-2023 (Graphic: Business Wire)

To learn more about the global trends impacting the future of market @Request for Free Sample Report

Vendor Landscape

DAIICHI SANKYO COMPANY, LIMITED, Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, and Pfizer Inc are among the vendors who have a strong position in the global market. While Astellas Pharma Inc., AstraZeneca, Eisai Co., Ltd., Assertio Therapeutics, Inc., and Shionogi & Co., Ltd. hold a favorable position in the global market.

DAIICHI SANKYO COMPANY, LIMITED newest product offerings include:

  • Tarlige: It is used to treat peripheral neuropathic pain.
  • VIMPAT Dry syrup: It is used to treat partial onset seizures in epilepsy patients with or without secondary generalization in Japan.

Get A Free Sample Analysis from theDiabetic Neuropathy Drugs Market

Eli Lilly and Company is another leading vendor in the diabetic neuropathy drugs market sphere. In line with the global diabetic neuropathy drugs market, the company’s newest product offerings include:

  • CYMBALTA: It is used to treat neuropathic pain.
  • Taltz (ixekizumab): It is used for the treatment of active psoriatic arthritis.

Johnson & Johnson Services, Inc. is another leading vendor in the diabetic neuropathy drugs market. In line with the global diabetic neuropathy drugs market, the company’s newest product offerings include:

  • NUCYNTA: It is an opioid analgesic used to treat diabetic neuropathy pain.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

KEY TOPICS COVERED:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: CUSTOMER LANDSCAPE

PART 07: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 08: MARKET SEGMENTATION BY MECHANISM OF ACTION

  • Market segmentation by mechanism of action
  • Comparison by mechanism of action
  • Calcium channel alpha-2-delta ligand - Market size and forecast 2018-2023
  • SNRIs and TCAs - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by mechanism of action

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

  • Market trends

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations

For more information about this report visithttps://www.technavio.com/report/global-diabetic-neuropathy-drugs-market-industry-analysis

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

Technavio is an international consulting and market research firm dedicated to empowering confident strategic decisions within the medical device, dental, pharmaceutical and more Healthcare industries.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191114005318/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email:media@technavio.com

Website: https://www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: DIABETES PHARMACEUTICAL HEALTH

SOURCE: Technavio Research

Copyright Business Wire 2019.

PUB: 11/14/2019 06:00 AM/DISC: 11/14/2019 06:01 AM

http://www.businesswire.com/news/home/20191114005318/en